Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ29KW
|
|||
| Drug Name |
FSI-189
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1 | [1] | |
| Company |
Gilead Sciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inhibitory receptor SHPS-1 (SIRPA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04502706) Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | T cells bring unconventional cancer-targeting to the clinic - again. Nat Biotechnol. 2020 Apr;38(4):389-391. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.